Martin Schuler
University Hospital, Essen · Westdeutsches Tumorzentrum, Universitätsklinikum Essen · AO Clinical Investigation and Documentation, Davos, Switzerland
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Martin Schuler as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04205552 · Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer PatientsUniversity Hospital, Essen · completed · NSCLC Stage II, NSCLC, Stage IIIA, NSCLC, Stage I · principal investigator
- Ph2NCT02488694 · Maintaining ERBB Blockade in EGFR-mutated Lung CancerAIO-Studien-gGmbH · terminated · Non-small-cell Lung Cancer With Somatic EGFR Mutations · principal investigator
- N/ANCT01316289 · Pilon Fracture Reduction and Functional OutcomeAO Clinical Investigation and Publishing Documentation · completed · Pilon Fracture of Tibia · study director
- Ph2NCT01197885 · Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal CancerGanymed Pharmaceuticals GmbH · completed · Solid Tumors · principal investigator
- Ph2NCT01051167 · Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal CancerMartin Schuler, Prof. Dr. med. · completed · Metastatic Colorectal Cancer · study director
- Ph1NCT00909025 · Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal CancerGanymed Pharmaceuticals GmbH · completed · Solid Tumors · principal investigator
- Ph2NCT00532025 · Sorafenib in Resected Non-small Cell Lung CarcinomaJohannes Gutenberg University Mainz · terminated · Carcinoma, Non-Small-Cell Lung · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:50 UTC. The ranking covers the 200 most relevant of 134 PubMed records, and a shared surname and initials can bring in a namesake. All 134 on PubMed
- Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol · 20132,733 citationsRCR 77.3
- 2,188 citationsRCR 101.7
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation.N Engl J Med · 20211,561 citationsRCR 84.2
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.N Engl J Med · 20151,444 citationsRCR 41.8
- 1,313 citationsRCR 39.5
- Ceritinib in ALK-rearranged non-small-cell lung cancer.N Engl J Med · 20141,179 citationsRCR 32.9
- 867 citationsRCR 16.5
- 862 citationsRCR 23.0
- 601 citationsRCR 22.0
- 557 citationsRCR 45.4